
    
      This is an open-label, Dose Escalation Study, multicenter phase I study to evaluate the
      safety and tolerability, determine the pharmacokinetics, and obtain preliminary information
      regarding pharmacodynamics and efficacy of MG1102 in subjects with solid tumor.

      Each subject will receive on dose of MG1102 followed by a 6-day rest period. If the initial
      dose is tolerated, subject will continue with the 21 days of MG1102 administration (5 days on
      treatment, 2 days off treatment for 3 weeks.) Subjects that have a tumor response as stable
      disease, may continue therapy on a compassionate use.

      Study Duration : for a minimum of 8 weeks
    
  